

4 November 2025

**BEXIMCO PHARMACEUTICALS LIMITED**

**Change of Name to Beximco Pharmaceuticals PLC.**

Beximco Pharmaceuticals Limited ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBB6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that the Company's proposed change of name, to Beximco Pharmaceuticals PLC., which was approved by shareholders at the Annual General Meeting of the Company on 29 December 2024, and notified on 30 December 2024, has now been approved and recorded by the Registrar of Joint Stock Companies and Firms (RJSC) in Bangladesh and will take effect on the AIM Market of the London Stock Exchange from 8.00 a.m. on 5 November 2025.

The Company's TIDM, "**BXP**", will remain unchanged as will its ISIN (US0885792061), SEDOL (BODM5S5) and LEI (213800IMBB6TIOQGB56) numbers.

GDR holders will be unaffected by the change of name, all legal instruments executed or issued in the former name of the Company shall continue to remain valid, binding, and enforceable as if executed or issued in the new name, pursuant to Section 11(8) of the Companies Act, 1994 and existing share/depository receipts certificates should be retained and remain valid.

For further information please visit [www.beximcopharma.com](http://www.beximcopharma.com) or enquire to:

**Beximco Pharma**

Mohammad Ali Nawaz, Chief Financial Officer  
Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS  
Executive Director & Company Secretary  
Tel: +880 2 41060531, Ext. 10140

**SPARK Advisory Partners Limited (Nominated Adviser)**

Mark Brady / Andrew Emmott  
Tel: +44 (0)20 3368 3551 / 3555

**SP Angel Corporate Finance LLP (Broker)**

Matthew Johnson  
Tel: +44 (0) 20 3470 0470

**FTI Consulting**

Simon Conway / Sam Purewal  
Tel: +44 (0)20 3727 1000

**Notes to Editors**

**About Beximco Pharma**

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CANUOUNRVSUARAA